"Just a heads up, but last year when AMRN announced the late breaking abstract acceptance the stock price sold off pretty hard."

Correct. There was a lot of skepticism of REDUCE-IT succeeding based upon the past failure of ALL other omega-3 related cardiovascular outcomes trials.

"I felt that the announcement was misunderstood and that topline results would be delayed until the AHA meeting in November when of course the topline data was released less than two weeks later."

Not sure how anyone could have misunderstood it the way you describe. In the exact same news release announcing the AHA late breaking presentation, Amarin stated "As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018." Even in bold in the first sentence of the news release it stated "Topline Results of the REDUCE-IT Study Anticipated Before End of September 2018."

Things can't be more clear than that. It is extremely rare for cardiovascular outcomes trial results to be first revealed at a major conference like AHA without first announcing top-line data sometime within the 3 months prior. 

BearDownAZ